Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders

Brain Research Bulletin

Volumn 76, Issue 5, 2008, Pages 469-473

  Cleary, C ^a   Linde, J A S ^b   Hiscock, K M ^b   Hadas, I ^c   Belmaker, R H ^c   Agam, G ^c   Flaisher Grinberg, S ^b   Einat, H ^a,b  

^a UNIVERSITY OF MINNESOTA DULUTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Affective disorders; Animal models; Autophagy; Depression; Forced swim test; mTOR; Tail suspension test

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FORCED SWIMMING TEST; MALE; MOOD DISORDER; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MOOD DISORDERS; MOTOR ACTIVITY; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 44549087727     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.03.005     Document Type: Article

References (45)

1. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., and Rubinsztein D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15 (2006) 433-442 (Epub 2005 Dec, 2020)
2. Bersudsky Y., Shaldubina A., and Belmaker R.H. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav. Pharmacol. 18 (2007) 77-80
3. Brunton L.L., Lazo J.S., and Parker K.L. Goodman and Gilman The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, NY
4. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., Eiermann W., Hess D., Morant R., Semiglazov V., Borner M., Salzberg M., Ostapenko V., Illiger H.J., Behringer D., Bardy-Bouxin N., Boni J., Kong S., Cincotta M., and Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5314-5322 (Epub 2005 Jun, 5313)
5. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T., and Leeds P. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar. Disord. 4 (2002) 129-136
6. Cryan J.F., and Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry 9 (2004) 326-357
7. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
8. Duman R.S. Synaptic plasticity and mood disorders. Mol. Psychiatry 7 (2002) S29-S34
9. Einat H. Chronic oral administration of ginseng extract results in behavioral change but has no effects in mice models of affective and anxiety disorders. Phytother. Res. 21 (2007) 62-66
10. Einat H., Clenet F., Shaldubina A., Belmaker R.H., and Bourin M. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav. Brain Res. 118 (2001) 77-83
11. Einat H., Karbovski H., Korik J., Tsalah D., and Belmaker R.H. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology (Berl.) 144 (1999) 158-162
12. Einat H., and Manji H.K. Cellular plasticity cascades: gene to behavior pathways in animal models of bipolar disorder. Biol. Psychiatry 59 (2006) 1960-1971
13. Einat H., Yuan P., Szabo S.T., Dogra S., and Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55 (2007) 123-131
14. Erlich S., Alexandrovich A., Shohami E., and Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol. Dis. 26 (2007) 86-93 (Epub 2007 Jan, 2031)
15. Ferron G.M., Mishina E.V., Zimmerman J.J., and Jusko W.J. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin. Pharmacol. Ther. 61 (1997) 416-428
16. Floto R.A., Sarkar S., Perlstein E.O., Kampmann B., Schreiber S.L., and Rubinsztein D.C. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 3 (2007) 620-622 (Epub 2007 Aug, 2016)
17. Gould T.D., Einat H., Bhat R., and Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. (2004) 1-4
18. Gould T.D., Einat H., O'Donnell K.C., Picchini A.M., Schloesser R.J., and Manji H.K. beta-Catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 14 (2007) 14
19. Gould T.D., O'Donnell K.C., Dow E.R., Du J., Chen G., and Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 54 (2008) 577-587 (Epub 2007 Nov, 2017)
20. Gould T.D., Picchini A.M., Einat H., and Manji H.K. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug. Targets 7 (2006) 1399-1409
21. Heimberger A.B., Wang E., McGary E.C., Hess K.R., Henry V.K., Shono T., Cohen Z., Gumin J., Sawaya R., Conrad C.A., and Lang F.F. Mechanisms of action of rapamycin in gliomas. Neuro-Oncology, 1522-8517 7 (2005) 1-11
22. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., Ziman B.D., Wang S., Ytrehus K., Antos C.L., Olson E.N., and Sollott S.J. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 113 (2004) 1535-1549
23. Kulkarni J., Garland K.A., Scaffidi A., Headey B., Anderson R., de Castella A., Fitzgerald P., and Davis S.R. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31 (2006) 543-547 (Epub 2005 Dec, 2013)
24. Leseux L., Laurent G., Laurent C., Rigo M., Blanc A., Olive D., and Bezombes C. PKC zeta-mTOR pathway: a new target for Rituximab therapy in follicular lymphoma. Blood 12 (2007) 12
25. Levine J. Controlled trials of inositol in psychiatry. Eur. Neuropsychopharmacol. 7 (1997) 147-155
26. Levine J., Barak Y., Gonzalves M., Szor H., Elizur A., Kofman O., and Belmaker R.H. Double-blind, controlled trial of inositol treatment of depression. Am. J. Psychiatry 152 (1995) 792-794
27. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray N.A., Zarate Jr. C.A., and Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53 (2003) 707-742
28. Meijer A.J., and Codogno P. Regulation and role of autophagy in mammalian cells. Int. J. Biochem. Cell Biol. 36 (2004) 2445-2462
29. Murgia M.G., Jordan S., and Kahan B.D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49 (1996) 209-216
30. Porsolt R.D. Animal model of depression. Biomedicine 30 (1979) 139-140
31. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
32. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int. Pharmacodyn. Ther. 229 (1977) 327-336
33. Porsolt R.D., Chermat R., Lenegre A., Avril I., Janvier S., and Steru L. Use of the automated tail suspension test for the primary screening of psychotropic agents. Arch Int. Pharmacodyn. Ther. 288 (1987) 11-30
34. Ravikumar B., and Rubinsztein D.C. Can autophagy protect against neurodegeneration caused by aggregate-prone proteins?. Neuroreport 15 (2004) 2443-2445
35. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., and Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36 (2004) 585-595 (Epub 2004 May, 2016)
36. Sanftner L.M., Rivera V.M., Suzuki B.M., Feng L., Berk L., Zhou S., Forsayeth J.R., Clackson T., and Cunningham J. Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol. Ther. 13 (2006) 167-174 (Epub 2005 Aug, 2026)
37. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., Cook L.J., and Rubinsztein D.C. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170 (2005) 1101-1111
38. Sarkar S., Perlstein E.O., Imarisio S., Pineau S., Cordenier A., Maglathlin R.L., Webster J.A., Lewis T.A., O'Kane C.J., Schreiber S.L., and Rubinsztein D.C. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3 (2007) 331-338 (Epub 2007 May, 2007)
39. Sarkar S., and Rubinsztein D.C. Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy 2 (2006) 132-134 (Epub 2006 Apr, 2006)
40. Sehgal S.N., Baker H., and Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28 (1975) 727-732
41. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
42. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
43. Tang S.J., Reis G., Kang H., Gingras A.C., Sonenberg N., and Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 467-472 (Epub 2001 Dec, 2026)
44. Zarate Jr. C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., and Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar. Disord. 9 (2007) 561-570
45. Zhang L., Yu J., Pan H., Hu P., Hao Y., Cai W., Zhu H., Yu A.D., Xie X., Ma D., and Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 19023-19028 (Epub 12007 Nov, 19016)